Davos BioSciences AG (DBS) was founded as a non-profit Biotech SME and spin-off of the Kühne Foundation to support the pharma industry in developing new medicine. For that purpose, it is primarily using the CK-CARE registry and biobank. Earnings are used to finance allergy research of CK-CARE.
DBS provides high-quality expertise in biobanking and laboratory services to help pharmaceutical companies in their effort to accelerate and optimise the discovery and development of new therapeutic agents and biomarkers as well as validation of markers and products to meet regulatory requirements. As of today, the main expertise is on atopic dermatitis as well as for other allergic diseases and for other disorders of the immune system.